A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04667117 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis

Interventions

BIOLOGICAL: Quadrivalent influenza vaccine
DRUG: Ofatumumab
DRUG: iDMT

Sponsor

Novartis Pharmaceuticals